Efficacy of saxagliptin combined with acarbose in the treatment of newly diagnosed type 2 diabetes mellitus / 中国生化药物杂志

ABSTRACT

Objective To investigate the clinical effect and analysis of Shah Glenn Dean combined with acarbose in the treatment of newly diagnosed elderly patients with type 2 diabetes mellitus.Methods 60 cases of newly diagnosed elderly patients treated in our hospital during the period from January 2015 to January 2017 in patients with type 2 diabetes mellitus is selected as the object of this study, they were randomly divided into control group and study group, 30 cases in each group.The control group was treated with acarbose treatment, the study group was treated with Shah Glenn Dean combined acarbose treatment, treatment time was 3months, glycosylated hemoglobin, after two groups of patients were in different treatment of hypoglycemia were observed and compared the rate of change, body mass index and blood glucose level changes.Results The patients in the control group, the incidence of hypoglycemia was 23.33%, patients in the study group, the incidence of hypoglycemia was 6.67%, patients in the study group,the incidence of hypoglycemia was significantly lower than that of control group, the difference was statistically significant between the groups(P <0.05); glycosylated hemoglobin levels in the study group were significantly lower than that of the control group of two patients, the difference was statistically significant between the groups(P <0.05); the total cost of the patients in the treatment group compared with the control group had no significant difference, the difference was not statistically significant.Conclusion Significant clinical therapeutic effect of saxagliptin combined with acarbose in the treatment of newly diagnosed elderly patients with type 2 diabetes, can make the patient's blood glucose levels were significantly lower,with high security, the incidence of hypoglycemia was significantly reduced, but also can reduce the weight of patients, the total cost in the course of treatment did not increase that will not cause economic burden on patients, it is worthy of clinical application.